BMRN Overview
Upcoming Projects (BMRN)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (BMRN)
-
Exploring the current treatment landscape for Hemophilia A & B, including CSL Behring's Hemgenix (etranacogene dezaparvovec-drlb) and Biomarin's potential gene therapy ROCTAVIAN (valoctocogene roxaparvovec)
Tickers: BMRN, CSLLY, QURE
Executed On: Apr 25, 2023 at 09:00 AM EDT -
Digging into the recent Phase 2 Cohort 5 results of Bridgebio's ifigratinib in achondroplasia
Tickers: BBIO, BMRN, ASND
Executed On: Mar 17, 2023 at 11:00 AM EDT -
Discussing the treatment landscape for hemophilia A with a focus on Biomarin's Roctavian (Valoctocogene Roxaparvovec) & Sanofi's Altuviiio (efanesoctocog alfa)
Tickers: BMRN, SNY
Executed On: Mar 08, 2023 at 02:00 PM EST -
A Second View: Examining the achondroplasia treatment landscape with a focus on BBIO's infigratinib, BMRN's Voxzogo (vosoritide) & ASND's TransCon CNP
Tickers: BBIO, BMRN, ASND
Executed On: Jan 31, 2023 at 12:00 PM EST -
Examining the achondroplasia treatment landscape with a focus on BBIO's infigratinib, BMRN's Voxzogo (vosoritide) & ASND's TransCon CNP
Tickers: BBIO, BMRN, ASND
Executed On: Jan 12, 2023 at 12:00 PM EST -
A Second View: Discussing the recent phase 2 results from infigratinib in children with achondroplasia and how it may compare to Biomarin's Voxzogo (vosoritide)
Tickers: BBIO, BMRN
Executed On: Aug 03, 2022 at 02:00 PM EDT -
Discussing the recent phase 2 results from infigratinib in children with achondroplasia and how it may compare to Biomarin's Voxzogo (vosoritide)
Tickers: BBIO, BMRN
Executed On: Aug 02, 2022 at 12:00 PM EDT -
Checking in with a prescriber of Voxzogo (vosoritide) in Achondroplasia, as the first FDA approved drug to improve growth in children with most common form of dwarfism
Tickers: BMRN, ASND
Executed On: Apr 08, 2022 at 02:00 PM EDT
Expired Projects (BMRN)
-
Discussing BioMarin’s ROCTAVIAN (valoctocogene roxaparvovec-rvox)for treating Severe Hemophilia A
Ticker: BMRN
Execute By: Aug 31, 2023 -
Digging into the recent Phase 3 results for Biomarin’s vosoritide (BMN 111) in achondroplasia
Ticker: BMRN
Execute By: Jun 30, 2020 -
Looking at Rubius' lead pipeline candidate, RTX-134 in phenylketonuria (PKU)
Tickers: RUBY, BMRN
Execute By: Jan 31, 2019
Upcoming & Overdue Catalysts (BMRN)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (BMRN)
-
BioMarin (BMRN) C1-INH treatment of hereditary angioedema granted FDA orphan designation
Ticker: BMRN
Occurred on: Dec 20, 2021 -
PDUFA date for Biomarin's (BMRN) VOXZOGO (Vosoritide) in Achondroplasia extended by three months to November 20, 2021
Ticker: BMRN
Occurred on: Nov 19, 2021 -
BioMarin (BMRN) Receives FDA Fast Track Designation for PKU Investigational Gene Therapy, BMN 307
Ticker: BMRN
Occurred on: Oct 02, 2020 -
FDA Approves Biomarin's (BMRN) Palynziq (pegvaliase-pqpz) Injection for Treatment of Adults with Phenylketonuria (PKU)
Ticker: BMRN
Occurred on: May 24, 2018 -
BioMarin's (BMRN) Phase 1/2 Study in Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A data released
Ticker: BMRN
Occurred on: May 22, 2018 -
Preliminary read out of open label Phase 3 study in DMD of eteplirsen
Tickers: SRPT, BMRN, PTCT
Occurred on: Dec 27, 2017 -
Data from First Set of 24-week Biopsies Expected Q2 or Q3 for UK Enrolled DMD patients in the Ongoing PhaseOut DMD trial
Tickers: SMMT, BMRN, SRPT, PTCT
Occurred on: Jun 22, 2017 -
BioMarin (BMRN) Expects Decision from CHMP and EU on CLN2 Disease Treatment Brineura in Q3 2017
Ticker: BMRN
Occurred on: Jun 01, 2017 -
BioMarin's (BMRN) BLA Approved by FDA for Brineura (Cerliponase Alfa) in Treatment of Batten Disease
Ticker: BMRN
Occurred on: Apr 27, 2017 -
BioMarin's BMN-270 Hemophilia A updated data to be presented at JPM 2017
Ticker: BMRN
Occurred on: Jan 09, 2017 -
Sarepta's (SRPT) Eteplirsen Approved by FDA for Duchenne Muscular Dystrophy After Long Approval Process
Tickers: SRPT, BMRN
Occurred on: Sep 19, 2016 -
BioMarin's (BMRN) Marketing Application for CLN2 Disease Treatment Ceriponase Alfa Approved by EMA
Ticker: BMRN
Occurred on: Sep 15, 2016 -
BioMarin Announces Withdrawal of Market Authorization Application for Kyndrisa (drisapersen) in Europe
Ticker: BMRN
Occurred on: May 31, 2016 -
FDA Advisory committee meeting for Sarepta Therapeutics' Eteplirsen
Tickers: SRPT, PTCT, BMRN
Occurred on: Apr 25, 2016 -
BioMarin Provides Encouraging Preliminary Data on First 8 Patients in Hemophilia A Gene Therapy Program
Ticker: BMRN
Occurred on: Apr 20, 2016 -
BioMarin Provides Program Update on Vosoritide in Achondroplasia
Ticker: BMRN
Occurred on: Apr 20, 2016 -
BioMarin Phase 3 Study of Pegvaliase for Phenylketonuria (PKU) Meets Primary Endpoint of Blood Phenylalanine (Phe) Reduction (p<0.0001)
Ticker: BMRN
Occurred on: Mar 21, 2016 -
Phase 3 data of PEG-PAL for Phenylketonuria (PKU) due March/April 2016
Ticker: BMRN
Occurred on: Mar 21, 2016 -
Phase 1/2 data of cerliponase alfa for Batten Disease due 1Q 2016
Ticker: BMRN
Occurred on: Mar 02, 2016 -
BioMarin to Present Results from Phase 1/2 Study of BMN 190 on CLN2 Disease at 12th Annual WORLDSymposium
Ticker: BMRN
Occurred on: Mar 02, 2016 -
FDA Grants Orphan Drug Designation to Biomarin's BMN-270 for Hemophilia A
Ticker: BMRN
Occurred on: Mar 01, 2016 -
FDA decision on Drisapersen approval in DMD: PDUFA 12/27/15
Tickers: BMRN, SRPT, PTCT
Occurred on: Jan 14, 2016 -
PDUFA date of Kyndrisa (drisapersen) for DMD originally set for December 27, 2015, now due for early January 2016
Ticker: BMRN
Occurred on: Jan 14, 2016 -
FDA Will Review BioMarin's (BMRN) New Drug Application for Duchenne Muscular Dystrophy Candidate Drisapersen on November 24, 2015
Tickers: BMRN, SRPT, PTCT
Occurred on: Nov 24, 2015
Strategic Initiatives (BMRN)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
